Sae Rom Chung1, Jung Hwan Baek2, Young Jun Choi1, Jeong Hyun Lee1. 1. Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. 2. Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea. radbaek@naver.com.
Abstract
OBJECTIVES: The purpose of this study was to evaluate the longer-term efficacy of ultrasound (US)-guided radiofrequency ablation (RFA) for treating locally recurrent papillary thyroid cancer (PTC). METHODS: We retrospectively reviewed 29 patients who underwent RFA for 46 recurrent PTC between September 2008 and April 2012 and were subsequently followed up for at least 5 years. Follow-up included size change on US and thyroglobulin (Tg) level at 1, 3, 6, and 12 months and every 6-12 months thereafter. Any complications were reported during follow-up. RESULTS: The mean follow-up duration after RFA was 80 ± 17.3 months (range, 60-114 months). Tumor volume decreased significantly, from 0.25 ± 0.42 mL before ablation to 0.01 ± 0.08 mL at the final evaluation (p < 0.001), with a mean volume reduction of 99.5% ± 2.9%. Forty-two of the 46 treated tumors (91.3%) had completely disappeared by the final evaluation. The mean serum Tg level decreased from 2.55 ± 4.7 to 0.75 ± 1.83 ng/dL (p < 0.001). There were no delayed complications associated with RFA during the follow-up period. CONCLUSIONS: RFA seems to be an effective minimally invasive therapy for the treatment of locally recurrent PTC even in the longer-term period. KEY POINTS: • RFA is an effective local control treatment option for recurrent PTCs even in the longer-term period with mean tumor VRR of 99.5% and the complete disappearance of the treated tumors in 91.3%. • The mean serum Tg level decreased significantly after RFA and biochemical remission rate was 51.7%. • No delayed complication after RFA for local recurrent PTC.
OBJECTIVES: The purpose of this study was to evaluate the longer-term efficacy of ultrasound (US)-guided radiofrequency ablation (RFA) for treating locally recurrent papillary thyroid cancer (PTC). METHODS: We retrospectively reviewed 29 patients who underwent RFA for 46 recurrent PTC between September 2008 and April 2012 and were subsequently followed up for at least 5 years. Follow-up included size change on US and thyroglobulin (Tg) level at 1, 3, 6, and 12 months and every 6-12 months thereafter. Any complications were reported during follow-up. RESULTS: The mean follow-up duration after RFA was 80 ± 17.3 months (range, 60-114 months). Tumor volume decreased significantly, from 0.25 ± 0.42 mL before ablation to 0.01 ± 0.08 mL at the final evaluation (p < 0.001), with a mean volume reduction of 99.5% ± 2.9%. Forty-two of the 46 treated tumors (91.3%) had completely disappeared by the final evaluation. The mean serum Tg level decreased from 2.55 ± 4.7 to 0.75 ± 1.83 ng/dL (p < 0.001). There were no delayed complications associated with RFA during the follow-up period. CONCLUSIONS: RFA seems to be an effective minimally invasive therapy for the treatment of locally recurrent PTC even in the longer-term period. KEY POINTS: • RFA is an effective local control treatment option for recurrent PTCs even in the longer-term period with mean tumor VRR of 99.5% and the complete disappearance of the treated tumors in 91.3%. • The mean serum Tg level decreased significantly after RFA and biochemical remission rate was 51.7%. • No delayed complication after RFA for local recurrent PTC.
Authors: Osama Al-Saif; William B Farrar; Mark Bloomston; Kyle Porter; Matthew D Ringel; Richard T Kloos Journal: J Clin Endocrinol Metab Date: 2010-03-23 Impact factor: 5.958
Authors: Ian D Hay; Geoffrey B Thompson; Clive S Grant; Eric J Bergstralh; Catherine E Dvorak; Colum A Gorman; Megan S Maurer; Bryan McIver; Brian P Mullan; Ann L Oberg; Claudia C Powell; Jon A van Heerden; John R Goellner Journal: World J Surg Date: 2002-05-21 Impact factor: 3.352
Authors: Michael K Kim; Susan H Mandel; Zubair Baloch; Virginia A Livolsi; Jill E Langer; Liesje Didonato; Stephanie Fish; Randal S Weber Journal: Arch Otolaryngol Head Neck Surg Date: 2004-10
Authors: N A Samaan; P N Schultz; R C Hickey; H Goepfert; T P Haynie; D A Johnston; N G Ordonez Journal: J Clin Endocrinol Metab Date: 1992-09 Impact factor: 5.958
Authors: Arian Mansur; Tushar Garg; Apurva Shrigiriwar; Vahid Etezadi; Christos Georgiades; Peiman Habibollahi; Timothy C Huber; Juan C Camacho; Sherif G Nour; Alan Alper Sag; John David Prologo; Nariman Nezami Journal: Diagnostics (Basel) Date: 2022-05-24
Authors: Leonardo Rangel; Leonardo M Volpi; Elaine Stabenow; Jose Higino Steck; Erivelto Volpi; Jonathon O Russell; Ralph P Tufano Journal: World J Otorhinolaryngol Head Neck Surg Date: 2020-09-19
Authors: Ralph P Tufano; Pia Pace-Asciak; Jonathon O Russell; Carlos Suárez; Gregory W Randolph; Fernando López; Ashok R Shaha; Antti Mäkitie; Juan P Rodrigo; Luiz Paulo Kowalski; Mark Zafereo; Peter Angelos; Alfio Ferlito Journal: Front Endocrinol (Lausanne) Date: 2021-06-24 Impact factor: 5.555